Improving physical health and reducing substance use in psychosis

Not Applicable

Completed

• Conditions: Topic: Mental Health Research Network; Subtopic: Secondary complications; Disease: Severe Mental illness; Mental and Behavioural Disorders; Mental illness

• Registration Number: ISRCTN58667926
• Lead Sponsor: ational Institute for Health Research (NIHR) (UK)

Brief Summary

2013 protocol in: http://www.ncbi.nlm.nih.gov/pubmed/24131496 2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/27000113 2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/25961431 2017 results in: http://www.ncbi.nlm.nih.gov/pubmed/29284438 2017 cost-effectiveness results in: http://www.ncbi.nlm.nih.gov/pubmed/29273021

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-04-23
• Study Completion: 2014-03-01
• Last Update Posted: 16 July 2018

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 504

Inclusion Criteria

All patients within consenting CMHTs who meet the following criteria will be recruited to the study:
1. Aged between 18 - 65 years old, either sex
2. Have a diagnosis of psychotic disorder including International Classification of Diseases, version 10 (ICD-10) diagnosis F20-29, F31.2, F32.3, F33.3 but excluding first episode psychotic illness as these patients are participating in another study
3. Are registered on the enhanced level of the Care Approach Programme (CPA)

Exclusion Criteria

1. Patients with primary diagnosis of learning disability
2. Physical health problem that will independently impact on metabolic measures and substance use
3. Pregnancy as a health promotion intervention may interfere with the necessary care
4. Life threatening or terminal medical conditions in which intensive care is already provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Quality of life (QLS)<br>2. Metabolic syndrome components:<br>2.1. Waist circumference<br>2.2. Resting blood pressure<br>2.3. Fasting plasma glucose level, HbA1c, HOMA-IR<br>2.4. Triglyceride levels<br>2.5. HDL Cholesterol<br>3. Cost and cost-effectiveness of the HPI<br>4. Use of substances<br>5. PANSS score<br><br>Measured at baseline, 3 months, 12 months and 24 months.

Secondary Outcome Measures

Name	Time	Method
Specific measures related to each module will be carried out at the end of each module, such as:<br>1. Diabetes module (glycated haemoglobin and fasting glucose)<br>2. Substance use module (Time Line Follow Back), Nicotine Dependence Questionnaire<br>3. Exercise (IPAQ)<br>4. Diet (waist circumference, weight)<br><br>Measured at baseline, 3 months, 12 months and 24 months.